<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01325181</url>
  </required_header>
  <id_info>
    <org_study_id>NOV001</org_study_id>
    <nct_id>NCT01325181</nct_id>
  </id_info>
  <brief_title>Ranibizumab Versus Low-fluence Photodynamic Therapy in the Treatment of Chronic Central Serous Chorioretinopathy</brief_title>
  <official_title>Prospective Study on the Efficacy and Safety of Intravitreal Ranibizumab Versus Low-fluence Photodynamic Therapy in the Treatment of Chronic Central Serous Chorioretinopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jang Won Heo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Korea Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy and safety of intravitreal ranibizumab
      injection versus low-fluence PDT in the treatment of chronic CSC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Central serous chorioretinopathy (CSC) is characterized by serous detachment of the
      neurosensory retina. The pathophysiology of CSC is not certain and various theories are
      proposed including impaired function of retinal pigment epithelium (RPE), choroidal ischemia
      and choroidal hyperpermeability leading to RPE damage. Acute CSC with monofocal or paucifocal
      changes of RPE usually shows spontaneous resolution and has a favorable visual outcome.
      Chronic CSC is characterized by multifocal or diffuse decompensation of RPE associated with
      persistent detachment of neurosensory retina. This might lead to cystoid macular
      degeneration, foveal atrophy and damage to the foveal photoreceptor layer, consequently
      resulting in irreversible significant visual loss. Photodynamic therapy (PDT) was proposed
      for the treatment of chronic CSC. Modified parameters of PDT such as shortening of the time
      of laser emission and reduction of a total light energy have been suggested to reduce the
      irreversible damages induced by conventional PDT. Recently, intravitreal injection of
      antibody to vascular endothelial growth factor(VEGF) was proposed as a new treatment option
      based on the effect of anti-permeability. Several reports demonstrated acceptable outcomes
      after intravitreal bevacizumab injection, one of anti-VEGF agent. But the clinical results
      with ranibizumab are not reported yet. The purpose of this study is to compare the efficacy
      and safety of intravitreal ranibizumab injection versus low-fluence PDT in the treatment of
      chronic CSC.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants That Achieved Complete Resolution of Subretinal Fluid on OCT Without Rescue Treatment</measure>
    <time_frame>12 months</time_frame>
    <description>number of participants who achieved complete resolution of subretinal fluid on OCT without rescue treatment until the end of the study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in logMAR BCVA</measure>
    <time_frame>12 months</time_frame>
    <description>the changes from baseline in logMAR BCVA throughout the follow-up period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Central Foveal Thickness on OCT</measure>
    <time_frame>12 months</time_frame>
    <description>the change from baseline in central foveal thickness measured by OCT throughout the follow-up period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Leakage on Fluorescein Angiography</measure>
    <time_frame>12 months</time_frame>
    <description>number of participants who showed fluorescein leakage after primary or rescue treatment throughout the follow-up period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Choroidal Hyperpermeability on Indocyanine Green Angiography</measure>
    <time_frame>12 months</time_frame>
    <description>change from baseline in the status of choroidal perfusion and hyperpermeability on indocyanine green angiography throughout the follow-up period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Underwent Rescue Treatment</measure>
    <time_frame>12 months</time_frame>
    <description>number of participants who underwent rescue treatment: ranibizumab injections for the low-fluence PDT group and low-fluence PDT for the ranibizumab group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Event</measure>
    <time_frame>12 months</time_frame>
    <description>number of participants with adverse event throughout the follow-up period including procedure and drug-related adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Chronic Central Serous Chorioretinopathy</condition>
  <arm_group>
    <arm_group_label>Low-fluence PDT with Verteporfin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Half the regular laser fluence PDT(Visudyne®; Novartis); a total light energy of 25J/cm2, a light dose rate of 300mW/cm2. If subretinal fluid was sustained after primary treatment, rescue treatment(ranibizumab injection) was considered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ranibizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Consecutive Intravitreal injection of ranibizumab(Lucentis®, Novartis) 0.5mg/0.05ml for the first 3 months. If subretinal fluid was sustained after primary treatment, rescue treatment(low-fluence photodynamic therapy) was considered</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Verteporfin</intervention_name>
    <description>a 6mg/m2 infusion of verteporfin(Visudyne; Novartis)over 10 minutes followed by laser delivery</description>
    <arm_group_label>Low-fluence PDT with Verteporfin</arm_group_label>
    <other_name>Visudyne</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ranibizumab</intervention_name>
    <description>Consecutive intravitreal injection of ranibizumab(Lucentis®, Novartis) 0.5mg/0.05ml for the first 3 months</description>
    <arm_group_label>Ranibizumab</arm_group_label>
    <other_name>Lucentis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. best-corrected visual acuity (BCVA) between 0.0 and 1.0 logarithm of the minimal angle
             of resolution (logMAR)

          2. presence of subfoveal fluid persisting for 3 months or more on optical coherence
             tomography (OCT)

          3. presence of leakage and multifocal/diffuse RPE decompensation on fluorescein
             angiography (FA)

          4. choroidal vascular hyperpermeability and abnormal dilation of choroidal vasculature on
             indocyanine angiography (ICGA)

        Exclusion Criteria:

          1. previous treatment, such as laser photocoagulation, PDT, intravitreal injection of
             steroid or anti-VEGF agent

          2. evidence of choroidal neovascularization

          3. any other ocular diseases that could affect visual acuity

          4. systemic steroid treatment in the previous 12 months

          5. media opacity such as cataract that could interfere with adequate acquisition of OCT,
             FA and ICGA images
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jang Won Heo, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>• Department of Ophthalmology, Seoul National University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 25, 2011</study_first_submitted>
  <study_first_submitted_qc>March 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2011</study_first_posted>
  <results_first_submitted>April 2, 2013</results_first_submitted>
  <results_first_submitted_qc>April 5, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 27, 2013</results_first_posted>
  <last_update_submitted>April 5, 2013</last_update_submitted>
  <last_update_submitted_qc>April 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Jang Won Heo</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>Chronic central serous chorioretinopathy</keyword>
  <keyword>Ranibizumab</keyword>
  <keyword>Photodynamic therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Central Serous Chorioretinopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
    <mesh_term>Lactitol</mesh_term>
    <mesh_term>Verteporfin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Low-fluence PDT</title>
        </group>
        <group group_id="P2">
          <title>Ranibizumab</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Low-fluence PDT</title>
        </group>
        <group group_id="B2">
          <title>Ranibizumab</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.4" spread="8.2"/>
                    <measurement group_id="B2" value="48.9" spread="7.5"/>
                    <measurement group_id="B3" value="50.8" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in logMAR BCVA</title>
        <description>the changes from baseline in logMAR BCVA throughout the follow-up period</description>
        <time_frame>12 months</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants That Achieved Complete Resolution of Subretinal Fluid on OCT Without Rescue Treatment</title>
        <description>number of participants who achieved complete resolution of subretinal fluid on OCT without rescue treatment until the end of the study</description>
        <time_frame>12 months</time_frame>
        <population>All study eyes were analyzed using intention to treat principle and the last observation forward method</population>
        <group_list>
          <group group_id="O1">
            <title>Low-fluence PDT</title>
          </group>
          <group group_id="O2">
            <title>Ranibizumab</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants That Achieved Complete Resolution of Subretinal Fluid on OCT Without Rescue Treatment</title>
          <description>number of participants who achieved complete resolution of subretinal fluid on OCT without rescue treatment until the end of the study</description>
          <population>All study eyes were analyzed using intention to treat principle and the last observation forward method</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Central Foveal Thickness on OCT</title>
        <description>the change from baseline in central foveal thickness measured by OCT throughout the follow-up period</description>
        <time_frame>12 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Leakage on Fluorescein Angiography</title>
        <description>number of participants who showed fluorescein leakage after primary or rescue treatment throughout the follow-up period</description>
        <time_frame>12 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Choroidal Hyperpermeability on Indocyanine Green Angiography</title>
        <description>change from baseline in the status of choroidal perfusion and hyperpermeability on indocyanine green angiography throughout the follow-up period</description>
        <time_frame>12 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Underwent Rescue Treatment</title>
        <description>number of participants who underwent rescue treatment: ranibizumab injections for the low-fluence PDT group and low-fluence PDT for the ranibizumab group</description>
        <time_frame>12 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Event</title>
        <description>number of participants with adverse event throughout the follow-up period including procedure and drug-related adverse events</description>
        <time_frame>12 months</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Low-fluence PDT</title>
        </group>
        <group group_id="E2">
          <title>Ranibizumab</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jang Won Heo</name_or_title>
      <organization>Seoul National University Hospital</organization>
      <phone>82220720836</phone>
      <email>hjw68@snu.ac.kr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

